Naltrexone

Generic Name
Naltrexone
Brand Names
Contrave, Embeda, Vivitrol
Drug Type
Small Molecule
Chemical Formula
C20H23NO4
CAS Number
16590-41-3
Unique Ingredient Identifier
5S6W795CQM
Background

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Indication

Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.

Associated Conditions
Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
Associated Therapies
-
Clinical Trials
Related News

Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

Phase 1
Completed
Conditions
Opioid-use Disorder
Interventions
Drug: BICX104
Drug: Vivitrol
First Posted Date
2021-04-02
Last Posted Date
2023-08-16
Lead Sponsor
BioCorRx Inc
Target Recruit Count
24
Registration Number
NCT04828694
Locations
🇺🇸

Orange County Research Center, Tustin, California, United States

An Investigation of the Effects of Opioid Receptor Blockade on Changes in Self-esteem and Social Attention

Not Applicable
Completed
Conditions
Self Esteem
Interventions
Drug: Placebo
Drug: Naltrexone
First Posted Date
2021-02-17
Last Posted Date
2021-02-18
Lead Sponsor
McGill University
Target Recruit Count
35
Registration Number
NCT04757506

Impact of Colchicine and Low-dose Naltrexone on COVID-19

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Colchicine 0.6 mg
Drug: Naltrexone
First Posted Date
2021-02-16
Last Posted Date
2023-07-25
Lead Sponsor
HealthPartners Institute
Target Recruit Count
142
Registration Number
NCT04756128
Locations
🇺🇸

Regions Hospital, Saint Paul, Minnesota, United States

🇺🇸

Park Nicollet Methodist Hospital, Saint Louis Park, Minnesota, United States

RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response

First Posted Date
2021-02-04
Last Posted Date
2021-02-04
Lead Sponsor
University of Sao Paulo
Target Recruit Count
40
Registration Number
NCT04738773

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

Phase 2
Recruiting
Conditions
Painful Diabetic Neuropathy
Interventions
Drug: Naltrexone
Drug: Placebo
First Posted Date
2020-12-22
Last Posted Date
2023-08-23
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
35
Registration Number
NCT04678895
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Predicting Response to Naltrexone With Eye Tracking in Videogame Disorder

First Posted Date
2020-12-02
Last Posted Date
2020-12-22
Lead Sponsor
University of Sao Paulo
Target Recruit Count
40
Registration Number
NCT04649892
Locations
🇧🇷

Hospital das Clínicas da faculdade de medicina da Universidade de São Paulo, São Paulo, Brazil

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

Phase 2
Withdrawn
Conditions
Covid19
Interventions
Drug: Metformin
Drug: Naltrexone
First Posted Date
2020-10-27
Last Posted Date
2022-10-04
Lead Sponsor
AgelessRx
Registration Number
NCT04604678
Locations
🇺🇸

AgelessRx, Ann Arbor, Michigan, United States

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

First Posted Date
2020-10-27
Last Posted Date
2023-01-25
Lead Sponsor
AgelessRx
Target Recruit Count
36
Registration Number
NCT04604704
Locations
🇺🇸

AgelessRx, Ann Arbor, Michigan, United States

Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

First Posted Date
2020-08-05
Last Posted Date
2024-11-18
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
55
Registration Number
NCT04499950
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Phase 2
Not yet recruiting
Conditions
Opioid Dependence
Interventions
Drug: Vivitrol
Drug: Brixadi
First Posted Date
2020-07-01
Last Posted Date
2024-11-01
Lead Sponsor
University of Pennsylvania
Target Recruit Count
200
Registration Number
NCT04454411
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy